SIM
AXSM icon

Spark Investment Management’s Axsome Therapeutics AXSM Stock Holding History

Spark Investment Management’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-40,900
Closed -$115K – 644
2018
Q4 		$115K Buy
+40,900
New +$135K 0.01% 550

Other funds holding AXSM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $241M AUM 112.74% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Spark Investment Management's AXSM Position: Q1 2019 in Review

Spark Investment Management sold out of Axsome Therapeutics (AXSM) in Q1 2019, closing a stake of 40,900 shares — an estimated $115K sold.

Spark Investment Management first reported a position in AXSM in Q4 2018 and held it in 1 quarter. The position peaked at $115K in Q4 2018. 65 funds tracked by Wall St. Rank hold AXSM as of Q1 2019.

  • Spark Investment Management reported no remaining Axsome Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Spark Investment Management sold 40,900 Axsome Therapeutics shares in Q1 2019, an estimated $115K.
  • Spark Investment Management first reported a position in Axsome Therapeutics in Q4 2018 and held it in 1 quarter.
  • Spark Investment Management's Axsome Therapeutics position peaked at $115K in Q4 2018.
  • 65 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2019.

Based on Spark Investment Management's 13F filing for Q1 2019, filed 7 May 2019.